BriaCell Therapeutics And BriaPro Therapeutics Enter Into A Definitive Purchase Agreement Pursuant To Which BriaPro Has Agreed To Purchase BriaCell's Exclusive License To Develop And Commercialize Soluble CD80 As A Biologic Agent For The Treatment Of Cancer And Other Associated Assets

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), are pleased to announce that they have entered into a definitive purchase agreement (the "Purchase Agreement") pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 ("sCD80") as a biologic agent for the treatment of cancer and other associated assets (the "Transaction").